Advertisement

Expression Pattern and Prognostic Significance of Chemokines in Breast cancer: An Integrated Bioinformatics Analysis

Published:April 24, 2022DOI:https://doi.org/10.1016/j.clbc.2022.04.008

      Abstract

      Background

      Breast cancer (BC), one of the most prevalent malignancies, is the second major cause of mortality from cancer among women worldwide. Even though substantial progress has been made in breast cancer treatment, metastasis still accounts for the majority of the deaths. The tumor microenvironment (TME) comprising stromal and non-stromal components is central to tumor growth and development and is partly regulated by chemokines. Chemokines regulate immune cell trafficking, the development of stroma and play a key role in inflammation, a cancer hallmark.

      Methods

      In the present study, we used a bioinformatics approach to identify highly deregulated chemokines in BC patients. We performed expression analysis, survival analysis, gene ontology analysis, KEGG analysis, and protein-protein interaction network analysis of the deregulated chemokines using Gepia2, UALCAN, Kaplan-Meier Plotter, DAVID, and STRING tools.

      Results

      We identified >2-fold change (FC) increase in CXCL9/10/11/13 and >-2 FC decrease in CCL14/21/28, CXCL2/12 CX3CL1. Also, increased expression of CCL14, CCL21, CXCL13, CXCL9, CXCL12 correlated with better overall survival (OS) of BC patients.

      Conclusions

      Our results strongly indicate that chemokines may have potential biomarker characteristics, and the constructed PPI network contributed to an in-depth understanding of the chemokine networks. The deregulated chemokines may prove to be therapeutic targets for the effective management of BC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2020.
        CA: Cancer J Clin. 2020; 70: 7-30
        • DeSantis C.E.
        • Ma J.
        • Gaudet M.M.
        • et al.
        Breast cancer statistics, 2019.
        CA Cancer J Clin. 2019; 69: 438-451
        • Bolf E.L.
        • Sprague B.L.
        • Carr F.E.
        A linkage between thyroid and breast cancer: a common etiology?.
        Cancer epidemiol biomark prevent. 2019; 28: 643-649
        • Lei X.
        • Lei Y.
        • Li J.K.
        • et al.
        Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
        Cancer letter. 2020; 470: 126-133
        • Nagarsheth N.
        • Wicha M.S.
        • Zou W.
        Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.
        Nat rev. Immunol. 2017; 17: 559-572
        • Mollica Poeta V.
        • Massara M.
        • Capucetti A.
        • Bonecchi R.
        Chemokines and chemokine receptors: new targets for cancer immunotherapy.
        Front immunol. 2019; 10: 379
        • Mantovani A.
        • Savino B.
        • Locati M.
        • Zammataro L.
        • Allavena P.
        • Bonecchi R.
        The chemokine system in cancer biology and therapy.
        Cytokine growth fact rev. 2010; 21: 27-39
        • Mehraj U.
        • Mushtaq U.
        • Mir M.A.
        • et al.
        Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications.
        Semin. Cancer Biol. 2022; https://doi.org/10.1016/j.semcancer.2022.03.008
        • Tang Z.
        • Li C.
        • Kang B.
        • Gao G.
        • Li C.
        • Zhang Z.
        GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.
        Nucle acids res. 2017; 45: W98-W102
        • Goldman M.J.
        • Craft B.
        • Hastie M.
        • et al.
        Visualizing and interpreting cancer genomics data via the Xena platform.
        Nature biotechnol. 2020; 38: 675-678
        • Chandrashekar D.S.
        • Bashel B.
        • Balasubramanya S.A.H.
        • et al.
        UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses.
        Neoplasia (New York, N.Y.). 2017; 19: 649-658
        • Györffy B.
        • Lanczky A.
        • Eklund A.C.
        • et al.
        An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
        Breast cancer res treat. 2010; 123: 725-731
        • Huang da W.
        • Sherman B.T.
        • Lempicki R.A.
        Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.
        Nucleic acids res. 2009; 37: 1-13
        • Szklarczyk D.
        • Franceschini A.
        • Wyder S.
        • et al.
        STRING v10: protein-protein interaction networks, integrated over the tree of life.
        Nucleic acids res. 2015; 43: D447-D452
        • Shannon P.
        • Markiel A.
        • Ozier O.
        • et al.
        Cytoscape: a software environment for integrated models of biomolecular interaction networks.
        Genome res. 2003; 13: 2498-2504
        • Bader G.D.
        • Hogue C.W.
        An automated method for finding molecular complexes in large protein interaction networks.
        BMC bioinformatics. 2003; 4: 2
        • Marotta L.L.C.
        • Almendro V.
        • Marusyk A.
        • et al.
        The JAK2/STAT3 signaling pathway is required for growth of CD44+ CD24–stem cell–like breast cancer cells in human tumors.
        J clin investigat. 2011; 121: 2723-2735
        • Mortezaee K.
        CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis.
        Life Sci. 2020; 249117534
        • Mollica Poeta V.
        • Massara M.
        • Capucetti A.
        • Bonecchi R.
        Chemokines and chemokine receptors: new targets for cancer immunotherapy.
        Front. Immunol. 2019; 10: 379
        • Liubomirski Y.
        • Lerrer S.
        • Meshel T.
        • et al.
        Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer.
        Front immunol. 2019; 10: 757
        • Martinez-Ordoñez A.
        • Seoane S.
        • Cabezas P.
        • et al.
        Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.
        Oncogene. 2018; 37: 1430-1444
        • Sun Y.
        • Mao X.
        • Fan C.
        • et al.
        CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis.
        Tumor Biol. 2014; 35: 7765-7773
        • Xu C.
        • Zhao H.
        • Chen H.
        • Yao Q.
        CXCR4 in breast cancer: oncogenic role and therapeutic targeting.
        Drug design, development ther. 2015; 9: 4953
        • Wendt M.K.
        • Cooper A.N.
        • Dwinell M.B.
        Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.
        Oncogene. 2008; 27: 1461-1471
        • Roy L.D.
        • Sahraei M.
        • Schettini J.L.
        • Gruber H.E.
        • Besmer D.M.
        • Mukherjee P.
        Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches.
        BMC cancer. 2014; 14: 1-13
        • Pernas S.
        • Martin M.
        • Kaufman P.A.
        • et al.
        Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
        Lancet Oncol. 2018; 19: 812-824
        • Xu M.
        • Li D.
        • Yang C.
        • Ji J.-S.
        MicroRNA-34a inhibition of the TLR signaling pathway via CXCL10 suppresses breast cancer cell invasion and migration.
        Cell Physiol Biochem. 2018; 46: 1286-1304
        • Gao Y.J.
        • De Lin Liu S.L.
        • Yuan G.F.
        • Li L.
        • Zhu H.Y.
        • Cao G.Y.
        Down-regulation of CXCL11 inhibits colorectal cancer cell growth and epithelial-mesenchymal transition.
        OncoTargets ther. 2018; 11: 7333
        • Wang Y.
        • Xu H.
        • Si L.
        • et al.
        MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11.
        Prostate. 2018; 78: 479-490
        • Walser T.C.
        • Rifat S.
        • Ma X.
        • et al.
        Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer.
        Cancer res. 2006; 66: 7701-7707
        • Kundu N.
        • Ma X.
        • Brox R.
        • et al.
        The chemokine receptor CXCR3 isoform B drives breast cancer stem cells.
        Breast cancer: basic clin res. 2019; 131178223419873628
        • Ma J.J.
        • Jiang L.
        • Tong D.Y.
        • Ren Y.N.
        • Sheng M.F.
        • Liu H.C.
        CXCL13 inhibition induce the apoptosis of MDA-MB-231 breast cancer cells through blocking CXCR5/ERK signaling pathway.
        Eur Rev Med Pharmacol Sci. 2018; 22: 8755-8762
        • Biswas S.
        • Sengupta S.
        • Chowdhury S.R.
        • Jana S.
        • Mandal G.
        • Mandal P.K.
        • et al.
        CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.
        Breast cancer res treat. 2014; 143: 265-276
        • Yang C.
        • He L.
        • He P.
        • et al.
        Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway.
        Med oncol. 2015; 32: 14
        • Vicari A.P.
        • Ait-Yahia S.
        • Chemin K.
        • Mueller A.
        • Zlotnik A.
        • Caux C.
        Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms.
        J immunol (Baltimore, Md.: 1950). 2000; 165: 1992-2000
        • Lee J.M.
        • Lee M.H.
        • Garon E.
        • et al.
        Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration.
        Clin cancer res. 2017; 23: 4556-4568
        • Shields J.D.
        • Kourtis I.C.
        • Tomei A.A.
        • Roberts J.M.
        • Swartz M.A.
        Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.
        Science (New York, N.Y.). 2010; 328: 749-752
        • Schulz-Knappe P.
        • Mägert H.J.
        • Dewald B.
        • et al.
        HCC-1, a novel chemokine from human plasma.
        J exp med. 1996; 183: 295-299
        • Zhu M.
        • Xu W.
        • Wei C.
        • et al.
        CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis.
        Cell death dis. 2019; 10: 796
        • Gu Y.
        • Li X.
        • Bi Y.
        • et al.
        CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma.
        Aging. 2020; 12: 784-807
        • Liang Y.
        • Yi L.
        • Liu P.
        • et al.
        CX3CL1 involves in breast cancer metastasizing to the spine via the Src/FAK signaling pathway.
        J Cancer. 2018; 9: 3603-3612